Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates

Warrington, Pennsylvania, UNITED STATES

WARRINGTON, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the second quarter ended June 30, 2020 and provided key business updates. 

Key Business and Financial Updates

  • Completed an underwritten public offering of 3,172,413 units, offered at a price of $7.25 per unit, which included the full exercise of the underwriters’ over-allotment option. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $7.975 per share. The gross proceeds to Windtree from this offering, including the over-allotment, were approximately $23 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with the offering, Windtree’s common stock began trading on The Nasdaq Capital Market and began trading under the symbol “WINT” on May 20, 2020.

  • Presented a new subset analysis from a phase 2b study of istaroxime in patients hospitalized with acute heart failure at the American College of Cardiology 2020 virtual meeting. The new post-hoc analysis characterized the responses between Caucasian and Asian patients and showed the istaroxime dose of 0.5 µg/kg/min produced a similar response on E/e’, the primary study endpoint, and stroke volume index, an important measure of cardiac performance. The Company previously presented overall results of the study, where the primary endpoint demonstrated a significant improvement (p<0.05) in cardiac function at both istaroxime study doses.

  • Announced first patient enrolled in its AEROSURF Phase 2b Bridging Study in premature infants with respiratory distress syndrome (RDS). The Company also announced that all initial European trial sites are active and enrolling or able to enroll patients into its AEROSURF® Phase 2b bridging study in premature infants with respiratory distress syndrome (RDS). In addition, the Company announced that select patients in this study may be co-enrolled in an investigator-sponsored study, being run in parallel to the bridging study. The concomitant study will evaluate changes in cerebral electroencephalography (EEG) and cerebral oxygenation during surfactant administration. The bridging study is a multicenter, randomized, controlled study with masked treatment assignment in up to 90 premature infants 26 to 32 weeks gestational age receiving nasal continuous positive airway pressure for RDS. If successful, the bridging study is intended to complete the Phase 2 clinical program for AEROSURF and prepare the transition of clinical development to a Phase 3 program.

  • Announced the hiring of John Hamill as chief financial officer. Also, enhanced the team responsible for clinical execution with other new hires, including Dr. Pratap Paruchuru as executive director of clinical development, Catherine Kacprzycki as director of clinical operations and Tracy Rarick as head of operations and program management.

  • Hosted a business update call in June, highlighting the Company’s clinical programs in acute cardiovascular and pulmonary diseases.

“Windtree made considerable progress this quarter on both the business and clinical development fronts,” said Craig Fraser, president, and chief executive officer of Windtree. “We successfully completed a public offering and concurrently up-listed to The Nasdaq Capital Market, which provides us with the funding to support advancement of our lead clinical programs, and, we believe increases our market visibility as we move toward planned milestones with our multiple clinical and business development activities. We are focused on execution and look forward to an exciting second half of 2020 that we anticipate will include initiating the Phase 2b study in early cardiogenic shock in the third quarter, progressing toward a planned initial trial of our proprietary KL4 surfactant to impact key respiratory parameters in ventilated COVID-19 patients, and other development activity in line with our strategy.”

Select Financial Results for the Second Quarter ended June 30, 2020

For the second quarter ended June 30, 2020, the Company reported an operating loss of $7.9 million, compared to an operating loss of $6.5 million in the second quarter of 2019.

Research and development expenses were $4.5 million for the second quarter of 2020, compared to $3.4 million for the second quarter of 2019.  The increase in research and development expenses is primarily due to increases in direct program and active pharmaceutical ingredient costs.

General and administrative expenses for the second quarter of 2020 were $3.4 million, compared to $3.2 million for the second quarter of 2019.

The Company reported a net loss of $9.6 million ($0.63 per basic share) on 15.1 million weighted-average common shares outstanding for the quarter ended June 30, 2020, compared to a net loss of $6.4 million ($0.60 per basic share) on 10.7 million weighted average common shares outstanding for the comparable period in 2019.

As of June 30, 2020, the Company reported cash and cash equivalents of $31.5 million which is expected to be sufficient to fund operations through at least the next twelve months.  Subsequent to the end of the quarter, the Company received additional payment from its partner Lee’s Pharmaceutical Holdings (HK) Ltd. of approximately $1.4 million and paid down debt on its credit facility of approximately $2.3 million.

Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, which will be filed with the Securities and Exchange Commission on August 14, 2020, which includes detailed discussions about the Company’s business plans and operations, financial condition and results of operations.

About Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to save patients in their moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree is also developing AEROSURF® as a paradigm shifting non-invasive surfactant treatment for premature infants with respiratory distress syndrome, as well as evaluating other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions such as preventing lung injury. Also in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

For more information, please visit the Company's website at

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include: risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the company’s clinical trials or disruption in supply chain; the success and advancement of the  clinical development programs for istaroxime,  AEROSURF® and the Company’s other product candidates; the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, aerosol delivery systems (ADS) and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the FDA or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s  product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; and the rate and degree of market acceptance of the Company’s product candidates, if approved.  These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact Information:

Monique Kosse
LifeSci Advisors

Darren Opland, PhD
LifeSci Communications

6/30/2020 10-Q Workbook   
Balance Sheet   
Condensed Consolidated Balance Sheets   
(in thousands, except share and per share data)   
   June 30, 2020 December 31, 2019
Current Assets:   
 Cash and cash equivalents$31,515  $22,578 
 Prepaid expenses and other current assets 2,121   1,283 
  Total current assets 33,636   23,861 
Property and equipment, net 727   798 
Restricted cash 154   154 
Operating lease right-of-use assets 1,034   1,390 
Intangible assets 77,090   77,090 
Goodwill 15,682   15,682 
  Total assets$128,323  $118,975 
Current Liabilities:   
 Accounts payable$1,223  $1,708 
 Collaboration and device development payable, net 968   1,972 
 Accrued expenses 3,676   3,226 
 Operating lease liabilities - current portion 651   750 
 Loans payable - current portion 5,714   161 
  Total current liabilities 12,232   7,817 
Operating lease liabilities - non-current portion 506   794 
Loans payable - non-current portion -   4,608 
Restructured debt liability - contingent milestone payments 15,000   15,000 
Other liabilities 1,000   - 
Deferred tax liabilities 16,129   15,821 
  Total liabilities 44,867   44,040 
Stockholders' Equity:   
 Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares   
  issued and outstanding at June 30, 2020 and December 31, 2019 -   - 
 Common stock, $0.001 par value; 120,000,000 shares authorized   
  at June 30, 2020 and December 31, 2019; 16,868,756 and 13,697,419 shares issued at June 30, 2020 and December 31, 2019, respectively; 16,868,732 and 13,697,395 shares outstanding at June 30, 2020 and December 31, 2019, respectively 17   14 
 Additional paid-in capital 787,707   763,097 
 Accumulated deficit (701,214)  (685,122)
 Treasury stock (at cost); 24 shares (3,054)  (3,054)
  Total stockholders' equity 83,456   74,935 
Total liabilities & stockholders' equity$128,323  $118,975 

6/30/2020 10-Q Workbook         
Income Statement       
Condensed Consolidated Statements of Operations       
(in thousands, except per share data)       
   Three Months Ended Six Months Ended
   June 30, June 30,
    2020   2019   2020   2019 
 License revenue with affiliate$-  $158  $-  $198 
 Total revenues -   158   -   198 

 Research and development
 4,495   3,413   7,956   6,755 
 General and administrative 3,453   3,240   6,695   6,595 
 Total operating expenses 7,948   6,653   14,651   13,350 
Operating loss (7,948)  (6,495)  (14,651)  (13,152)
Other income (expense):       
 Interest income 5   39   94   99 
 Interest expense (31)  (117)  (75)  (253)
 Other income (expense), net (1,584)  136   (1,460)  332 
 Total other income (expense), net (1,610)  58   (1,441)  178 
Net loss$(9,558) $(6,437) $(16,092) $(12,974)
Net loss per common share       
 Basic and diluted$(0.63) $(0.60) $(1.12) $(1.21)
Weighted average number of common shares outstanding       
 Basic and diluted 15,091   10,730   14,394   10,722